{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:57:47Z","timestamp":1793969867357,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T00:00:00Z","timestamp":1456272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1053\/j.ajkd.2015.12.034","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T22:30:26Z","timestamp":1458599426000},"page":"84-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":276,"title":["Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial"],"prefix":"10.1053","volume":"68","clinical-trial-number":[{"clinical-trial-number":"nct01194973","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Fadi","family":"Fakhouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryvonne","family":"Hourmant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Campistol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spero R.","family":"Cataland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Osama","family":"Gaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Menne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico E.","family":"Minetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Prov\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent E.","family":"Weekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayo","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille L.","family":"Bedrosian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe M.","family":"Legendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1053\/j.ajkd.2015.12.034_bib1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2015.12.034_bib2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MNH.0b013e32833aff4a","article-title":"Thrombotic microangiopathies: new insights and new challenges","volume":"19","author":"Zipfel","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"10.1053\/j.ajkd.2015.12.034_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MNH.0b013e3283378f25","article-title":"Thrombotic microangiopathy: new insights","volume":"19","author":"Benz","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"10","key":"10.1053\/j.ajkd.2015.12.034_bib4","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on\u00a0clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.12.034_bib5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2015.12.034_bib6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2015.12.034_bib7","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","article-title":"Complement and the atypical hemolytic uremic syndrome in children","volume":"23","author":"Loirat","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"20","key":"10.1053\/j.ajkd.2015.12.034_bib8","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/blood-2009-03-205096","article-title":"Platelet-associated complement factor H in healthy persons and patients with atypical HUS","volume":"114","author":"Licht","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.ajkd.2015.12.034_bib9","first-page":"27","article-title":"An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A\u00a0consensus document","volume":"33","author":"Campistol","year":"2013","journal-title":"Nefrologia"},{"issue":"3","key":"10.1053\/j.ajkd.2015.12.034_bib10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal\u00a0transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2015.12.034_bib11","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the\u00a0treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1053\/j.ajkd.2015.12.034_bib12","unstructured":"US Food and Drug Administration. Soliris (eculizumab) [prescribing information]. Cheshire, CT: Alexion Pharmaceuticals, Inc;\u00a02014."},{"key":"10.1053\/j.ajkd.2015.12.034_bib13","unstructured":"European Medicines Agency. Soliris (eculizumab) [summary of product characteristics]. Paris, France; Alexion Europe SAS;\u00a02015."},{"issue":"23","key":"10.1053\/j.ajkd.2015.12.034_bib14","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2015.12.034_bib15","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2015.12.034_bib16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values","volume":"53","author":"Levey","year":"2007","journal-title":"Clin Chem"},{"issue":"5","key":"10.1053\/j.ajkd.2015.12.034_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"10.1053\/j.ajkd.2015.12.034_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1053\/j.ajkd.2015.12.034_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1053\/j.ajkd.2015.12.034_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"10.1053\/j.ajkd.2015.12.034_bib21","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2015.12.034_bib22","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA Reference Center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"issue":"16","key":"10.1053\/j.ajkd.2015.12.034_bib23","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood-2013-11-516237","article-title":"How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2015.12.034_bib24","unstructured":"European Medicines Agency. Bexsero (meningococcal group B vaccine) [European public assessment report]. Siena, Italy: Novartis;\u00a02013."},{"key":"10.1053\/j.ajkd.2015.12.034_bib25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s40267-014-0120-x","article-title":"Eculizumab: a guide to its use in atypical haemolytic uraemic syndrome","volume":"30","author":"Keating","year":"2014","journal-title":"Drugs Ther Perspect"},{"issue":"21","key":"10.1053\/j.ajkd.2015.12.034_bib26","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V120.21.3472.3472","article-title":"Eculizumab in paroxysmal nocturnal hemoglobinuria (PNH): a report of all 153 patients treated in the UK","volume":"120","author":"Hill","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.ajkd.2015.12.034_bib27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","article-title":"Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases","volume":"63","author":"Fakhouri","year":"2014","journal-title":"Am J Kidney Dis"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638616001591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638616001591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:52:41Z","timestamp":1759459961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638616001591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0272638616001591"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.12.034","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.12.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}